Marianna Irati Carrillo Encinales

Ms. Marianna Irati Carrillo Encinales

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
APAlexandra Porras-Ramirez
Alexandra Porras-Ramirez
AMAlejandro Rico Mendoza
Alejandro Rico Mendoza
LELiliana Encinales
Liliana Encinales
OMOscar Madiedo
Oscar Madiedo
MEMarianna Irati Carrillo Encinales
Marianna Irati Carrillo Encinales
AOAlejandra Hernández Osorio
Alejandra Hernández Osorio
Chimeric antigen receptor T-cell (CAR-T) treatment has revolutionized the therapeutic approach for relapsed or refractory hematologic malignancies. But its

9 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
ARAlejandro Rico-Mendoza
Alejandro Rico-Mendoza
APAlexandra Porras-Ramirez
Alexandra Porras-Ramirez
HGHeidy García-Orozco
Heidy García-Orozco
NDNatalia Delgado-Quiroz
Natalia Delgado-Quiroz
LELiliana Encinales
Liliana Encinales
JUJorge Urquijo-Mendez
Jorge Urquijo-Mendez
Sickle cell disease (SCD) is one of the most prevalent hemoglobinopathies worldwide, particularly in regions with high genetic predisposition. Early diagnosis through newborn screening (NBS) is critical for initiating interventions that significantly reduce morbidity and mortality. This systematic review evaluates the current methodologies used in NBS for SCD, comparing their sensitivity, specificity, and feasibility of implementation in different settings. We also explore recent innovations, including point-of-care (POC) tests and molecular diagnostics, that are transforming early detection strategies. Our findings suggest that while high-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS) remain gold-standard techniques, newer POC assays offer promising alternatives for resource-limited settings. The integration of artificial intelligence (AI) and genomic screening could further enhance diagnostic accuracy and accessibility. Future directions should focus on optimizing screening programs for global implementation and ensuring equity in early diagnosis.

14 August 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AMAlejandro Rico Mendoza
Alejandro Rico Mendoza
APAlexandra Porras
Alexandra Porras
LELiliana Encinales
Liliana Encinales
OMOscar Madiedo
Oscar Madiedo
MEMarianna Irati Carrillo Encinales
Marianna Irati Carrillo Encinales
RZRoberto Jurado Zambrano
Roberto Jurado Zambrano
Invasive aspergillosis and mucormycosis are life-threatening fungal infections characterized by high early mortality, substantial toxicity, and intensive healthcare resource utilization. While multiple antifungal therapies are recommended in international guidelines, their comparative clinical and economic value remains uncertain, particularly in resource-limited settings. We developed a hybrid decision tree and Markov model to evaluate antifungal strategies, including liposomal amphotericin B, isavuconazole, voriconazole, posaconazole, and caspofungin, from the perspective of the Colombian healthcare system over a 6-month horizon. Health states included clinical response, treatment failure, toxicity, and death. Outcomes included quality-adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs), and net monetary benefit (NMB). Deterministic and probabilistic sensitivity analyses were performed. In invasive aspergillosis, isavuconazole provided a modest incremental benefit over voriconazole (+0.022 QALYs), driven primarily by improved tolerability, at an incremental cost of COP 3.4 million, yielding an ICER of COP 154.5 million/QALY. In mucormycosis, liposomal amphotericin B yielded greater survival benefits (+0.035 QALYs) but at substantially higher costs (ICER: COP 494.3 million/QALY). Across willingness-to-pay thresholds, isavuconazole and voriconazole demonstrated more favorable economic profiles, owing to lower toxicity and reduced hospitalizations. These findings highlight that the clinical–economic value of antifungal therapy is primarily determined by early survival gains, toxicity burden, and front-loaded costs. Strategies minimizing toxicity and hospitalization appear more efficient in constrained health systems, whereas survival-maximizing approaches may be justified in severe disease. This integrated analysis supports context-specific antifungal decision-making in the management of invasive fungal infections.

22 July 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
STSarah R. Tritsch
Sarah R. Tritsch
JFJose Forero-Mejia
Jose Forero-Mejia
EMEvelyn Mendoza-Torres
Evelyn Mendoza-Torres
ASAlfonso Sucerquia
Alfonso Sucerquia
AAAbebawork Adem
Abebawork Adem
Aileen ChangAileen Chang
Aileen Chang
Chronic chikungunya arthritis is a debilitating post-viral inflammatory arthritis with no established evidence-based therapy. Regulatory T cell (Treg) dysfunction may contribute to persistent inflammation, and low-dose interleukin-2 (IL-2) may restore immune regulation. We evaluated the immunomodulatory effects of low-dose IL-2 using peripheral blood mononuclear cells from adults with laboratory-confirmed chronic chikungunya arthritis in Atlántico, Colombia. Cells were treated ex vivo with recombinant IL-2 or an IL-2/anti-IL-2 monoclonal antibody complex in the presence of CD2/CD3/CD28 stimulation beads, followed by flow cytometric assessment of effector T cells and Tregs. Low-dose IL-2 treatments ex vivo did not increase total Treg frequency but selectively increased activated suppressor Tregs while decreasing activated T effector cells, enhancing Treg CTLA-4 and HLA-DR expression, and reducing Ki67 expression in effector T cells. IL-2 complex treatment decreased cytokine-secreting Tregs, and IL-10 and TGF-β were not associated with IL-2 treatment status or with Teff/Treg balance, suggesting limited utility as pharmacodynamic biomarkers of low-dose IL-2 treatments. These findings support the use of activated suppressor Tregs, Treg CTLA-4, and HLA-DR expression as candidate biologic endpoints for evaluation in future trials of low-dose IL-2 in chikungunya arthritis.